https://clinicaltrials.gov/ct2/show/NCT03810183?type=Intr&cond=COPD&phase=01234&lupd_s=01%2F04%2F2019&lupd_d=14&sort=nwst A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia Condition : COPD Interventions : Drug: QAW039; Drug: Placebo Sponsor : Novartis Pharmaceuticals Not yet recruiting NCT03810183 Fri, 18 Jan 2019 12:00:00 EST
